New antibiotic strategy tested for vulnerable cancer patients
NCT ID NCT04673175
Summary
This study tested whether a specific antibiotic (ceftolozane-tazobactam) works better than standard antibiotics to treat serious Pseudomonas infections in people with blood cancers or who have had a stem cell transplant. Participants received the antibiotic for 10-14 days, and researchers checked if they were alive and their infection was improving 30 days later. The study also compared these results to similar patients from the past who received standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.